Sultamicillin: Antimicrobial activity and clinical investigation of respiratory tract infections

Seiichi Aonuma, Reiko Sasaki, Kikuo Onuma, Akira Watanabe, Masako Sasaki, Kotaro Oizumi, Kiyoshi Konno

    Research output: Contribution to journalArticlepeer-review

    1 Citation (Scopus)


    In vitro antimicrobial activity of Sultamicillin (SBTPC) which is a mutual prodrug of Ampicillin (ABPC) and Sulbactam (SBT), a potent inhibitor of many β-lactamases, was examined by an agar dilution method, and therapeutic efficacy of SBTPC in the treatment of patients with respiratory tract infections was evaluated. The minimum inhibitory concentrations (MICs) of SBTPC were compared with those of Cefaclor (CCL), ABPC and Cloxacillin (MCIPC) against following 20 strains each of clinical isolates; Staphylococcus aureus, Escherichia coli and Klebsiella pneumoniae and against 19 strains of Staphylococcus epidermidis. Reductions in the MICs of ABPC in the presence of SBT were observed in the strains of Escherichia coli and Klebsiella pneumoniae. Four patients with respiratory tract infections were administered SBTPC orally q.i.d. for five to seven days at a daily dose of four tablets. Clinical response to the treatment with the drug was good in three patients and poor in one patient. Out of three strains of Haemophilus influenzae which were recovered from the sputum of these patients at the start of the treatment with the drug, two strains were eradicated and the other was replaced by Streptococcus pneumoniae during the treatment with the drug. As regards adverse reactions, only slight degree of elevation of S-GOT and S-GPT was observed in one patient.

    Original languageEnglish
    Pages (from-to)185-189
    Number of pages5
    Publication statusPublished - 1985 Jan 1

    ASJC Scopus subject areas

    • Pharmacology (medical)
    • Infectious Diseases
    • Pharmacology
    • Drug Discovery
    • Oncology

    Fingerprint Dive into the research topics of 'Sultamicillin: Antimicrobial activity and clinical investigation of respiratory tract infections'. Together they form a unique fingerprint.

    Cite this